RxDoctor Payments Data

Benjamin Thomas, MD

Infectious Disease · Honolulu, HINPI 1164658019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Insmed, Inc. accounts for 89.3% of it on its own, with 7 other manufacturers making up the rest.

$2,715in general payments, 2019–2025

Across 164 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$2K
  • Viiv Healthcare Company$123
  • Cumberland Pharmaceuticals, Inc.$46
  • Gilead$44
  • Johnson & Johnson$24
  • Melinta Therapeutics, LLC$23
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$2,59696%
  • Education$1184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,715 in reported general payments places this provider in the 70th percentile of 28 infectious disease providers in Hawaii.

See all infectious disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$191,033
Medicare patients
387
Services billed
1,512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArikayceAmikacin Liposomal/Neb.Accessr16$245,633
NuzyraOmadacycline Tosylate11$176,798
ErtapenemErtapenem Sodium179$80,507
Daptomycin65$70,610
CresembaIsavuconazonium Sulfate11$67,715
CeftriaxoneCeftriaxone Sodium124$33,313
Vancomycin Hcl52$7,865
Cefepime Hcl22$7,078
Cefdinir63$5,725
Voriconazole14$5,640
Methenamine Hippurate46$4,053
Azithromycin35$2,662
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav49$1,772
Fosfomycin Tromethamine11$1,675
Doxycycline Hyclate47$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Insmed, Inc.Arikayce$2,425$245,63316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 infectious disease providers in Hawaii.

Other infectious disease in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →